

CURRICULUM VITAE

NAME: Dennis O. Dixon

TITLE AND AFFILIATION: Mathematical Statistician
Biostatistics Research Branch
National Institute of Allergy and Infectious Diseases
Bethesda, Maryland

BIRTH DATE AND PLACE: May 2, 1944
San Antonio, Texas

CITIZENSHIP: USA

HOME ADDRESS: 8921 Battery Place
Bethesda, MD 20814-2639

TELEPHONE: (301) 654-8526

OFFICE ADDRESS: NIH, NIAID
6700B Rockledge Drive - MSC 7609
Bethesda, MD 20892-7609

TELEPHONE: (301) 402-2306

EDUCATION:

1962 - 1966	B.S., Southern Methodist University Mathematics (with Honors)
1966 - 1968	M.S., Southern Methodist University Mathematical Statistics
1968 - 1970 1973 - 1974	Ph.D., The Johns Hopkins University Mathematical Statistics

MILITARY SERVICE:

1971 - 1972	Captain United States Air Force
-------------	------------------------------------

ACADEMIC AND PROFESSIONAL APPOINTMENTS:

6/02 – Present	Mathematical Statistician Biostatistics Research Branch, NIAID Bethesda, Maryland
8/97 – 5/02	Chief, Biostatistics Research Branch Division of AIDS, NIAID Rockville, Maryland
2/91 - 7/97	Chief, Coordinating Centers Branch Division of AIDS, NIAID Rockville, Maryland
7/90 - 7/97	Mathematical Statistician Biostatistics Research Branch Division of AIDS, NIAID Rockville, Maryland
7/77 - 6/90	Assistant - Associate Biometrician Assistant - Associate Professor of Biometrics Department of Biomathematics The University of Texas M.D. Anderson Cancer Center Houston, Texas
9/89 - 6/90	Associate Professor of Biomathematics, Biometry The University of Texas School of Public Health Houston, Texas
9/87 - 8/88	Cancer Expert Biometric Research Branch Division of Cancer Treatment National Cancer Institute National Institutes of Health Bethesda, Maryland
1976 - 1977	Senior Biostatistician Norwich Pharmacal Company Norwich, New York
1974 - 1976	Assistant Professor of Statistics Depts. of Statistics and Community Dentistry University of Florida Gainesville, Florida

EDITORIAL BOARD MEMBERSHIPS:

4/90 – 7/04	Associate Editor, <i>Biometrics</i>
-------------	-------------------------------------

ADVISORY COMMITTEE APPOINTMENTS:

Chair, Performance and Safety Monitoring Board, Radiosurgical Treatment of Temporal Lobe Epilepsy, National Institute of Neurological Disorders and Stroke, 2000 – present

Member, Data and Safety Monitoring Board, Double-Blind Study to Assess Safety, Tolerability and Immunogenicity of Live Attenuated Human Cytomegalovirus (HCMV) Vaccine Candidates vs. Placebo in Participants Who Have Pre-existing Immunity to HCMV, National Institute of Allergy and Infectious Diseases, 2000 – present

Member, Data and Safety Monitoring Board, Programs of Excellence in Gene Therapy for Heart, Lung, and Blood Diseases, National Heart, Lung, and Blood Institute, 2001 – 2006

Chair, Data Monitoring Committee, SubCutaneous Daclizumab in Uveitis, National Eye Institute, 2002

Member, Standing NIEHS Title 42 Review Committee, 2003 – 2008

Member, NIAID Institutional Review Board, 2003 – present; Vice Chair, 2005 -- present

Member, Internal Advisory Committee for the Biostatistics and Bioinformatics Shared Resource, Division of Biostatistics and Bioinformatics, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 2005 – present

Member, Data and Safety Monitoring Board, Cardiothoracic Surgical Network, National Heart, Lung, and Blood Institute, 2008 – present

HONORS:

Kappa Mu Epsilon

Sigma Tau Delta

Phi Beta Kappa

Who's Who Among Students in American Universities and Colleges

Southern Methodist University Blue Key

Arnold Air Society National Conclave Chairman

AFROTC Distinguished Military Graduate

NDEA Title IV Fellow

NIH Trainee

The Johns Hopkins University Department of Statistics Outstanding Graduate Student

Fellow, American Statistical Association

NIH Director's Awards, 2000, 2007

NIH Merit Award, 2001

NIH Clinical Center Director's Award, 2008

NIAID Merit Award, 2008

SOCIETIES:

American Statistical Association (Secretary, Southeast Texas Chapter, 1978 - 1980; Vice President, Houston Area Chapter, 1985 - 1986; President, Houston Area Chapter, 1986 - 1987; Houston Area Chapter Representative to Council of Chapters, 1988 - 1989; Secretary-Treasurer, Section on Bayesian Statistical Science, 1992 – 1993; Archives and Historical Materials Committee, 2000 -- 2005; Chair, Biometrics Section, 2004; President's Task Force on Engagement with Other Organizations, 2006 – 2007)

International Biometric Society

Society for Clinical Trials (Membership Committee, 1984 - 1987, 1989 - 1991; Publication Committee, 1995 – 2004, Chair, 1998 – 2004; Program Committee, 2001, 2002, 2007 Annual Meetings; President, 2005-2006)

International Society for Clinical Biostatistics (Program Committee, 1994 Annual Meeting)

BIBLIOGRAPHY

PUBLISHED ARTICLES IN REFEREED JOURNALS:

1. Dixon DO, Bland RP: "A Bayes Solution for the Problem of Ranking Poisson Parameters." *Annals of the Institute of Statistical Mathematics* **23**:119-124, 1971.
2. Dixon DO, Duncan DB: "Minimum Bayes Risk t Intervals for Multiple Comparisons." *Journal of the American Statistical Association* **70**:822-31, 1975.
3. Dixon DO: "Interval Estimates Derived from Bayes Testing Rules." *Journal of the American Statistical Association* **71**:406-408, 1976.
4. Ringelberg ML, Francis AP, Plummer RW, Dixon DO: "A Comparison of Gingival Health and Gingival Crevicular Fluid Flow in Diabetic and Non-Diabetic Children." *Journal of Dental Research* **56**:108-111, 1977.
5. Ringelberg ML, Webster DB, Dixon DO: "Effects of an Amine Fluoride Dentifrice and Mouthrinse on Dental Caries of School Children After 18 Months." *Journal of Preventive Dentistry* **5**:26, 28-30, 1978.
6. Wein AJ, Hanno PM, Dixon DO, Benson GS: "The Reproducibility and Interpretation of Carbon Dioxide Cystometry." *Journal of Urology* **120**:205-206, 1978.
7. Wein AJ, Hanno PM, Dixon DO, Raezer DM, Benson GS: "The Effect of Oral Bethanechol Chloride on the Cystometrogram of the Normal Male Adult." *Journal of Urology* **120**:330-331, 1978.
8. Ringelberg ML, Webster DB, Dixon DO, LeZotte DC: "The Caries Preventive Effect of Amine Fluorides and Inorganic Fluorides in a Mouth-rinse or Dentifrice after 30 Months of Use." *Journal of American Dental Association* **98**:202-208, 1979.
9. Ringelberg ML, Webster DB, Dixon DO, Fairchild S, Driscoll WS: "Results of Gingival, Plaque, and Stain Assessments after 30 Months Use of Amine Fluorides and Their Inorganic Counterparts." *Pharmacology and Therapeutics in Dentistry* **4**:27-31, 1979.
10. Rivkin SE, Gottlieb JA, Thigpen T, El Mawla G, Saiki J, Dixon D: "Methyl CCNU and Adriamycin for Patients with Metastatic Sarcomas." *Cancer* **46**:446-451, 1980.
11. Al-Sarraf M, Eyre H, Bonnet J, Saiki J, Gagliano R, Pugh R, Lehane D, Dixon D, Bottomley R: "Study of Tamoxifen in Metastatic Renal Cell Carcinoma and the Influence of Certain Prognostic Factors: A Southwest Oncology Group Study." *Cancer Treatment Reports* **65**:447-451, 1981.
12. Alexanian R, Salmon S, Gutterman J, Dixon D, Bonnet J, Haut A: "Chemoimmunotherapy for Multiple Myeloma." *Cancer* **47**:1923-1929, 1981.

13. Weick JK, Jones SE, Haut A, Fisher R, Dixon D: "Treatment of Recurrent Lymphomas with Vincristine, BCNU, Doxorubicin, and Prednisone (VBAP): A Southwest Oncology Group Study." *Cancer Treatment Reports* **65**:611-614, 1981.
14. Costanzi J, Fabian C, Wilson H, Dixon D: "Sequential Combination Chemotherapy for Disseminated Melanoma. A Southwest Oncology Group Study." *Cancer Treatment Reports* **65**:732-734, 1981.
15. Costanzi JJ, Al-Sarraf M, Groppe C, Bottomley R, Fabian C, Neidhart J, Dixon D: "Combination Chemotherapy Plus BCG in the Treatment of Disseminated Malignant Melanoma: A Southwest Oncology Group Study." *Medical and Pediatric Oncology* **10**:251-258, 1982.
16. Bonnet J, Alexanian R, Salmon S, Bottomley R, Amare M, Haut A, Dixon D: "Vincristine, BCNU, Doxorubicin, and Prednisone (VBAP) Combination in the Treatment of Relapsing or Resistant Multiple Myeloma: A Southwest Oncology Group Study." *Cancer Treatment Reports* **66**:1267-1271, 1982.
17. Nathwani BN, Dixon DO, Jones SE, Hartsock RJ, Rebuck JW, Byrne GE, Jr, Sheehan WW, Kim H, Coltman CA, Jr, Rappaport H: "The Clinical Significance of the Morphologic Subdivision of Diffuse, 'Histiocytic' Lymphoma: A Study of 162 Patients Treated by the Southwest Oncology Group." *Blood* **60**:1068-1074, 1982.
18. Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Talley R, Butler JJ, Byrne GE, Jr, Hartsock R, Dixon D, Salmon SE: "Improved Complete Remission Rates and Survival for Patients with Large Cell Lymphoma Treated with Chemoimmunotherapy: A Southwest Oncology Group Study." *Cancer* **51**:1083-1090, 1983.
19. Jones SE, Haut A, Weick JK, Wilson HE, Grozea P, Fabian CJ, McKelvey E, Byrne GE, Jr, Hartsock R, Dixon DO, Coltman CA, Jr: "Comparison of Adriamycin-Containing Chemotherapy (MOP-BAP) with MOPP-Bleomycin in the Management of Advanced Hodgkin's Disease: A Southwest Oncology Group Study." *Cancer* **51**:1339-1347, 1983.
20. Gagliano R, Levin H, El-Bolkainy MN, Wilson HE, Stephens RL, Fletcher WS, Rivkin SE, O' Bryan RM, Coltman CA, Jr, Saiki JH, Stuckey WJ, Balducci L, Bonnet JD, Dixon DO: "Adriamycin versus Adriamycin plus Cis-Diamminedichloroplatinum (DDP) in Advanced Transitional Cell Bladder Carcinoma: A Southwest Oncology Group Study." *American Journal of Clinical Oncology (CCT)* **6**:215-218, 1983.
21. Salmon SE, Haut A, Bonnet J, Amare M, Weick J, Durie BGM, Dixon D: "Alternating Combination Chemotherapy Improves Survival in Multiple Myeloma: A Southwest Oncology Group Study." *Journal of Clinical Oncology* **1**:453-461, 1983.
22. Weick JK, Antunez A, Kraus TA, Fabian CJ, Dixon D: "The Combined Modality Therapy of Diffuse Histology Non-Hodgkin's Lymphoma with Cyclophosphamide, Adriamycin, Vincristine, Prednisone (CHOP) and Total Body Irradiation." *International Journal of Radiation Oncology, Biology, and Physics* **9**:1205-1207, 1983.
23. Witherspoon RP, Legha SS, Reimer RR, Talley RW, Stuckey WJ, Dixon DO, McCracken JD, Stephens RL, Oishi N: "Phase II Trial of Amsacrine in Metastatic or Locally

Recurrent Squamous Cell Carcinoma from Head and Neck Primaries: A Southwest Oncology Group Study." *Cancer Treatment Reports* **68**:435-436, 1984.

24. Bonnet JD, Alexanian R, Salmon SE, Haut A, Dixon DO: "Addition of Cisplatin and Bleomycin to Vincristine-Carmustine-Doxorubicin-Prednisone (VBAP) Combination in the Treatment of Relapsing or Resistant Multiple Myeloma: A Southwest Oncology Group Study." *Cancer Treatment Reports* **68**:481-485, 1984.
25. Kantarjian HM, Mclaughlin P, Fuller LM, Dixon DO, Osborne BM, Cabanillas FF: "Follicular Large Cell Lymphoma: Analysis and Prognostic Factors in 62 Patients." *Journal of Clinical Oncology* **2**:811-819, 1984.
26. Weick JK, Jones SE, Grozea PN, Fabian CJ, Dixon DO: "Vindesine, Carmustine, Doxorubicin, and Prednisone (EBAP) in Recurrent Lymphomas: A Southwest Oncology Group Study." *Cancer Treatment Reports* **68**:963-967, 1984.
27. Metter GE, Nathwani BN, Burke JS, Winberg CD, Mann RB, Barcos M, Kjeldsberg CR, Whitcomb CC, Dixon DO, Miller TP, Jones SE: "Morphologic Subclassification of Follicular Lymphoma: Variability of Diagnoses among Hematopathologists, A Collaborative Study Between the Repository Center and Pathology Panel for Lymphoma Clinical Studies." *Journal of Clinical Oncology* **3**:35-38, 1985.
28. Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ: "Comparison of Methotrexate and Cisplatin for Patients with Advanced Squamous Cell Carcinoma of the Head and Neck Region: A Southwest Oncology Group Study." *Cancer Treatment Reports* **69**:577-581, 1985.
29. Barlogie B, Alexanian R, Smith L, Dixon D, Smallwood L, Delasalle K: "Prognostic Implications of Tumor Cell DNA and RNA Content in Multiple Myeloma." *Blood* **66**:338-341, 1985.
30. Jones SE, Grozea PN, Miller TP, Van Slyck EJ, Balcerzak SP, Costanzi JJ, Morrison FS, Eyre HJ, Fabian CJ, Dabich L, Dixon DO, Hartsock RJ, Grogan TM, Kjeldsberg C, Schnitzer B: "Chemotherapy with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Alone or with Levamisole or with Levamisole Plus BCG for Malignant Lymphoma: A Southwest Oncology Group Study." *Journal of Clinical Oncology* **3**:1318-1324, 1985.
31. Liliemark JO, Plunkett W, Dixon DO: "Relationship of 1-beta-D-Arabinofuranosylcytosine in Plasma to 1-beta-D-Arabinofuranosyl-cytosine 5'-Triphosphate Levels in Leukemic Cells During Treatment With High-Dose 1-beta-D-Arabinofuranosylcytosine." *Cancer Research* **45**:5952-5957, 1985.
32. Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PN, Wilson HE: "Effect of Age on Therapeutic Outcome in Advanced Diffuse Histiocytic Lymphoma: The Southwest Oncology Group Experience." *Journal of Clinical Oncology* **4**:295-305, 1986.
33. Thames HD, Brock WA, Bock SP, Dixon DO: "Effect of Dose per Fraction on the Division Potential of Lethally Irradiated Plateau Phase CHO Cells Exposed to Isoeffective Fractionation Regimens." *British Journal of Cancer* **53**:376-381, 1986.

34. Alexanian R, Barlogie B, Dixon D: "High-Dose Glucocorticoid Treatment of Resistant Myeloma." *Annals of Internal Medicine* **105**:8-11, 1986.
35. Durie BGM, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, Salmon SE, Dabich L, Files JC, Costanzi JJ: "Improved Survival Duration with Combination Chemotherapy Induction for Multiple Myeloma: A Southwest Oncology Group Study." *Journal of Clinical Oncology* **4**:1227-1237, 1986.
36. Ota DM, Nishioka K, Grossie B, Dixon D: "Erythrocyte Polyamine Levels during Intravenous Feeding of Patients with Colorectal Carcinoma." *European Journal of Cancer and Clinical Oncology* **22**:837-842, 1986.
37. Nathwani BN, Metter GE, Miller TP, Burke JS, Mann RB, Barcos M, Kjeldsberg CR, Dixon DO, Winberg CD, Whitcomb CC, Jones SE: "What Should Be the Morphologic Criteria for the Subdivision of Follicular Lymphomas?" *Blood* **68**:837-845, 1986.
38. Schultheiss TE, Thames HD, Peters LJ, Dixon DO: "Effect of Latency on Calculated Complication Rates." *International Journal of Radiation Oncology, Biology, and Physics* **12**:1861-1865, 1986.
39. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M: "Prognosis of Chronic Lymphocytic Leukemia: A Multivariate Regression Analysis of 325 Untreated Patients." *Blood* **69**:929-936, 1987.
40. McLaughlin P, Fuller LM, Velasquez WS, Butler JJ, Hagemeister FB, Sullivan-Halley JA, Dixon DO: "Stage III Follicular Lymphoma: Durable Remissions with a Combined Chemotherapy-Radiotherapy Regimen." *Journal of Clinical Oncology* **5**:867-874, 1987.
41. Trantum BL, Dixon D, Quagliana J, Neidhart J, Balcerzak SP, Costanzi JJ, Fabian CJ, Neilan B, Maloney T, O' Bryan RM, Groppe C.: "Lack of Benefit of Adjunctive Chemotherapy in Stage I Malignant Melanoma: A Southwest Oncology Group Study." *Cancer Treatment Reports* **71**:643-644, 1987.
42. Dixon DO, McLaughlin P, Hagemeister FB, Freireich EJ, Fuller LM, Cabanillas FF, Gehan EA: "Reporting Outcomes in Hodgkin's Disease and Lymphoma." *Journal of Clinical Oncology* **5**:1670-1672, 1987.
43. Barlogie B, Stass S, Dixon D, Keating M, Cork A, Trujillo JM, McCredie KB, Freireich EJ: "DNA Aneuploidy in Adult Acute Leukemia." *Cancer Genetics and Cytogenetics* **28**:213-228, 1987.
44. Dixon DO, Divine GW: "Multiple Comparisons for Relative Risk Regression: Extension of the *k*-Ratio Method." *Statistics in Medicine* **6**:591-597, 1987.
45. Estey E, Plunkett W, Dixon D, Keating M, McCredie K, Freireich EJ: "Variables Predicting Response to High-Dose Cytosine Arabinoside Therapy in Patients with Refractory Acute Leukemia." *Leukemia* **1**:580-583, 1987.
46. Estey EH, Keating MJ, Dixon DO, Trujillo JM, McCredie KB, Freireich EJ: "Karyotype Is Prognostically More Important than the FAB System's Distinction between

- Myelodysplastic Syndrome and Acute Myelogenous Leukemia." *Hematologic Pathology* **1**:203-208, 1987.
47. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ: "Characteristics of Accelerated Disease in Chronic Myelogenous Leukemia." *Cancer* **61**:1441-1446, 1988.
 48. Alexanian R, Barlogie B, Dixon D: "Prognosis of Asymptomatic Multiple Myeloma." *Archives of Internal Medicine* **148**:1963-1965, 1988.
 49. Zander AR, Keating M, Dicke K, Dixon D, Pierce S, Jagannath S, Peters L, Horwitz L, Cockerill K, Spitzer G, Vellekoop L, Kantarjian H, Walters R, McCredie K, Freireich EJ: "A Comparison of Marrow Transplantation with Chemotherapy for Adults with Acute Leukemia of Poor Prognosis in First Complete Remission." *Journal of Clinical Oncology* **6**:1548-1557, 1988.
 50. Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabanillas F: "Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma." *Blood* **72**:2015-2019, 1988.
 51. Dixon DO, Simon R: "Sample Size Considerations for Studies Comparing Survival Curves Using Historical Controls." *Journal of Clinical Epidemiology* **41**:1209-1213, 1988.
 52. Bentzen SM, Thames HD, Travis EL, Ang KK, van der Schueren E, Dewit L, Dixon DO: "Direct Estimation of Latent Time for Radiation Injury in Late-Responding Normal Tissues: Gut, Lung, and Spinal Cord." *International Journal of Radiation Biology* **55**:27-43, 1989.
 53. Ventura GJ, Hester JP, Dixon DO, Khorana S, Keating MJ: "Analysis of Risk Factors for Fatal Hemorrhage During Induction Therapy of Patients with Acute Promyelocytic Leukemia." *Hematologic Pathology* **3**:23-28, 1989.
 54. Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB, Gutterman JU: "Treatment of Poor-Prognosis, Newly Diagnosed Acute Myeloid Leukemia with ara-C and Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor." *Blood* **75**:1766-1769, 1990.
 55. Lippman SM, Peters EJ, Wargovich MJ, Stadnyk AN, Dixon DO, Dekmezian RH, Loewy JW, Morice RC, Cunningham JE, Hong WK: "Bronchial Micronuclei as a Marker of an Early Stage of Carcinogenesis in the Human Tracheobronchial Epithelium." *International Journal of Cancer* **45**:811-815, 1990.
 56. Alexanian R, Barlogie B, Dixon D: "Renal Failure in Multiple Myeloma: Pathogenesis and Prognostic Implications." *Archives of Internal Medicine*, **150**:1693-1695, 1990.
 57. Barlogie B, Jagannath S, Dixon DO, Cheson B, Smallwood L, Hendrickson A, Purvis JD, Bonnem E, Alexanian R: "High-Dose Melphalan and Granulocyte-Macrophage Colony-Stimulating Factor for Refractory Multiple Myeloma." *Blood* **76**:677-680, 1990.

58. Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, Lemaistre FC, Smallwood L, Pruitt K, Dixon DO: "Autologous Bone Marrow Transplantation in Multiple Myeloma: Identification of Prognostic Factors." *Blood* **76**:1860-1866, 1990.
59. Hagemeister FB, Fuller LM, Velasquez WS, McLaughlin P, Redman JR, Swan F, Rodriguez MA, North L, Dixon D, Silvermintz K, Cabanillas F: "Two cycles of MOPP and radiotherapy: Effective treatment for stage IIIA and IIIB Hodgkin's disease." *Annals of Oncology* **2**:25-31, 1991.
60. Dixon DO, Simon R: "Bayesian Subset Analysis." *Biometrics* **47**:871-881, 1991.
61. Dixon DO, Simon R: "Bayesian Subset Analysis in a Colorectal Cancer Clinical Trial." *Statistics in Medicine* **11**:13-22, 1992.
62. Spinolo JA, Cabanillas F, Dixon DO, Khorana SM, McLaughlin P, Velasquez WS, Hagemeister FB, Redman JR, Swan F Jr: "Therapy of Relapsed or Refractory Low-grade Follicular Lymphomas: Factors Associated with Complete Remission, Survival and Time to Treatment Failure." *Annals of Oncology* **3**:227-232, 1992.
63. Brant LJ, Duncan DB, Dixon DO: k -Ratio t tests for multiple comparisons involving several treatments and a control." *Statistics in Medicine* **11**:863-873, 1992.
64. Dixon DO, Rida WN, Fast PE, Hoth DF: "HIV vaccine trials: Some design issues including sample size calculation." *Journal of Acquired Immune Deficiency Syndromes* **6**:485-496, 1993.
65. Dubray B, Henry-Amar M, Meerwaldt JH, Noordijk EM, Dixon DO, Cosset J-M, Thames HD: "Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: The role of fractionation." *Radiotherapy and Oncology* **36**:211-217, 1995.
66. Albert JM, Ioannidis JPA, Reichelderfer P, Conway B, Coombs RW, Crane L, DeMasi R, Dixon DO, Flandre P, Hughes MD, Kalish LA, Larntz K, Lin D, Marschner IC, Munoz A, Murray J, Neaton J, Pettinelli C, Rida W, Taylor JMG, Welles SL: "Statistical issues for HIV surrogate endpoints: Point/counterpoint." *Statistics in Medicine* **17**:2435-2462, 1998.
67. Ioannidis JPA, Dixon DO, McIntosh M, Albert JM, Bozzette SA, Schnittman SA: "Relationship between event rates and treatment effects in clinical site differences within multicenter trials: An example from primary *Pneumocystis carinii* prophylaxis." *Controlled Clinical Trials* **20**:253-266, 1999.
68. Dixon DO, Lagakos SW: "Should data and safety monitoring boards share confidential interim data?" *Controlled Clinical Trials* **21**:1-6, 2000.
69. DeMets D, Califf R, Dixon D, Ellenberg S, Fleming T, Held P, Julian D, Kaplan R, Levine R, Neaton J, Packer M, Pocock S, Rockhold F, Seto B, Siegel J, Snapinn S, Stump D, Temple R, Whitley R: "Issues in regulatory guidelines for data monitoring committees." *Clinical Trials* **1**:162-169, 2004.
70. Grady C, Wagman J, Ssekubugu R, Wawer MJ, Serwadda D, Kiddugavu M, Nalugoda F, Gray RH, Wendler D, Dong Q, Dixon DO, Townsend B, Wahl E, Emanuel EJ:

"Research benefits for hypothetical HIV vaccine trials: The views of Ugandans in the Rakai District." *IRB: Ethics & Human Research* **30**:1-7, 2008.

INVITED ARTICLES:

1. Dixon DO: "Sample Size for Clinical Studies." *Cancer Bulletin* **32**:207-213, 1980.
2. Jones SE, Coltman CA Jr, Grozea PN, DePersio EJ, Dixon DO: "Conclusions from the Clinical Trials of the Southwest Oncology Group." *Cancer Treatment Reports* **66**:847-853, 1982.
3. Coltman CA Jr, Dixon DO: "Second Malignancies Complicating Hodgkin's Disease: A Southwest Oncology Group 10-Year Follow-up." *Cancer Treatment Reports* **66**:1023-1033, 1982.
4. Dixon DO: "Prognostic Factors and Clinical Trials." *Oncology* **4**:116-122, 1990.
5. Duncan DB, Dixon DO: "Comment" (on D'Agostino RB, Heeren TC: "Multiple comparisons in over-the-counter drug clinical trials with both positive and placebo controls." *Statistics in Medicine* **10**:1-6, 1991). *Statistics in Medicine* **10**:21-26, 1991.
6. Ellenberg SS, Dixon D: "Statistical issues in designing clinical trials of AIDS treatments and vaccines." *Journal of Statistical Planning and Inference* **42**:123-135, 1994.
7. Dixon, DO: "Discussion" (of Wei LJ and Glidden D: "An overview of statistical methods for multiple events data.") *Statistics in Medicine* **16**:843-845, 1997.
8. Dixon D, Legler J: "Careers in Biostatistics: High Demand and Rewarding Work." *STATS* **37**:3-7, 2003.
9. Dickersin K, Davis BR, Dixon DO, George SL, Hawkins BS, Lachin J, Peduzzi P, Pocock S: "The Society for Clinical Trials supports United States legislation mandating trials registration." *Clinical Trials* **1**:417-420, 2004.
10. SCT Working Group on Data Monitoring: Dixon DO, Freedman RS, Herson J, Hughes M, Kim KM, Silverman MH, Tangen CM: "Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees." *Clinical Trials* **3**:314-319, 2006.
11. DeMets DL, Stormo G, Boehnke M, Louis TA, Taylor J, Dixon D: "Training of the next generation of biostatisticians: A call to action in the U.S." *Statistics in Medicine* **25**:3415-3429, 2006.
12. Dixon D: "Foreword: Statistical methods in HIV/AIDS." *Statistics in Medicine* **27**:4635, 2008.

BOOK CHAPTERS:

1. Al-Sarraf M, Costanzi JJ, Dixon DO: "Levamisole and Chemotherapy for Disseminated Melanoma." In: *Tumor Progression*, R. Crispen (ed.) Elsevier North Holland, Inc.: 1980; pp. 221-231.
2. Al-Sarraf M, Costanzi JJ, Dixon DO: "Chemoimmunotherapy for Disseminated Melanoma (DM)." In: *Tumor Progression*, R. Crispen (ed.) Elsevier North Holland, Inc.: 1980; pp. 333-343.
3. Salmon S, Alexanian R, Dixon D: "Chemoimmunotherapy for Multiple Myeloma: Effect of Levamisole during Maintenance: Preliminary Report of a Southwest Oncology Group Study." In: *Immunotherapy of Human Cancer*, WD Terry, SA Rosenberg (editors). Elsevier North Holland, Inc.: 1981; pp. 61-66.
4. Coltman CA Jr, Myers JW, Montague E, Fuller LA, Grozea PN, DePersio EJ, Dixon DO: "The Role of Combined Radiotherapy and Chemotherapy in the Primary Management of Hodgkin's Disease: Southwest Oncology Group Studies." In: *Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment*, S Rosenberg, H Kaplan (editors). Academic Press, Inc.: 1982; pp. 523-536.
5. Coltman CA Jr, Saiki JH, Panettiere FJ, Balcerzak SP, Stephens RL, Morrison FS, Dixon DO, Von Hoff DD: "Mitoxantrone Hydrochloride in Hematologic Malignancies: Southwest Oncology Group Phase II Studies." In: *New Anticancer Drugs: Mitoxantrone and Bisantrone*, M Rozenzweig, DD Von Hoff, MJ Staquet (editors). Raven Press: 1983; pp. 115-124.
6. Duncan DB, Dixon DO: " k -Ratio t Tests, t Intervals and Estimates for Multiple Comparisons." In: *Encyclopedia of Statistical Sciences*, Vol. 4, S Kotz, NL Johnson (eds). John Wiley & Sons, Inc.: 1983; pp. 403-410.
7. Coltman CA Jr, Frei E III, Montague E, Grozea PN, DePersio EJ, Fabian CJ, Mansfield CM, Jones SE, Dixon DO: "Combined Modality Treatment of Advanced Hodgkin's Disease: Southwest Oncology Group Studies." In: *Management of Advanced Cancer*, P Periman, E Savlov (eds). Masson Publishing, USA., Inc.: 1983; pp. 79-112.
8. O'Bryan RM, Coltman CA Jr, Grimsley S, Pass LM, Dixon DO: "Southwest Oncology Group - Cancer Control Program." In: *Advances in Cancer Control: Epidemiology and Research*, PF Engstrom, PN Anderson, LE Mortenson (editors). Alan R. Liss, Inc.: 1984; pp. 33-38.
9. Grozea PN, DePersio EJ, Coltman CA Jr, Fabian CJ, Morrison FS, Dixon DO, Jones SE: "Chemotherapy Alone Versus Combined Modality Therapy for Stage III Hodgkin's Disease: A Five-Year Follow-up of a Southwest Oncology Group Study (SWOG-7518)." In: *Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances*, F Cavalli, G Bonnadonna, M Rozenzweig (editors). Martinus Nijhoff Publishing: 1985; pp. 345-351.
10. Fabian CJ, Mansfield CM, Dixon DO, Jones SE, Grozea PN, Morrison FS, Weick JK, O'Bryan RM: "Incidence of Liver Involvement and Correlation of Biopsy Results with Ann Arbor Clinical Criteria and Response to Chemotherapy in Advanced Hodgkin's Disease: A Southwest Oncology Group Study." In: *Malignant Lymphomas and*

Hodgkin's Disease: Experimental and Therapeutic Advances, F Cavalli, G Bonnadonna, M Rozenzweig (editors). Martinus Nijhoff Publishing: 1985; pp. 409-416.

11. Coltman CA Jr, Jones SE, Grozea PN, DePersio EJ, Dixon DO: "Bleomycin in Combination with MOPP in the Management of Advanced Hodgkin's Disease: A Southwest Oncology Group Experience." In: *Bleomycin Chemotherapy*, BI Sikic, M Rozenzweig, S Carter (editors). Academic Press, Inc.: 1985, pp. 137-153.
12. Walters RS, Johnston DA, Dixon DO, Stass SA, Keating MJ, Trujillo JM, McCredie KB, Barlogie B: "Nucleic Acid Flow Cytometry: An Aid to Diagnosis and Prognosis in Acute Leukemia in Adults." In: *The Acute Leukemias: Biologic, Diagnostic, and Therapeutic Determinants*, SA Stass (editor). Marcel Dekker, Inc.: 1987, pp. 203-245.
13. Schultheiss TE, Dixon DO, Peters LJ, Thames HD: "Calculation of Late Complication Rates for Use in Optimization Algorithms." In: *The Use of Computers in Radiation Therapy*, IAD Bruinvis, PH van der Giessen, HJ van Kleffens, FW Wiitkaemper (editors). Elsevier Science Publishers B.V. (North-Holland): 1987, pp. 127-129.
14. Loeffler M, Dixon DO, Swindell R: "Prognostic Factors of Stage III and IV Hodgkin's Disease." In: *Treatment Strategy in Hodgkin's Disease*, R Somers, M Henry-Amar, JH Meerwaldt, P Carde (editors). Colloque INSERM/John Libbey Eurotext Ltd.: 1990, pp. 89-103.
15. Dixon DO, Albert JM: "Issues in the Design and Analysis of AIDS Clinical Trials." In: *Recent Advances in Clinical Trial Design and Analysis*, PF Thall (editor). Kluwer Academic Publishers: 1995, pp. 29-47.
16. Simon R, Dixon D, Freidlin B: "A Bayesian Model for Evaluating Specificity of Treatment Effects in Clinical Trials." In: *Recent Advances in Clinical Trial Design and Analysis*, PF Thall (editor). Kluwer Academic Publishers: 1995, pp. 155-175.
17. Simon R, Dixon DO, Freidlin B: "Bayesian Subset Analysis of a Clinical Trial for the Treatment of HIV Infections." In: *Bayesian Biostatistics*, DA Berry, DK Stangl (editors). Marcel Dekker, Inc.: 1996, pp. 555-576.
18. Dixon D: "Merrell, Margaret." In: *Encyclopedia of Biostatistics*, T Colton and P Armitage (eds). John Wiley & Sons, Inc.: 1997; p. 2569.
19. Dixon D: "Pearl, Raymond." In: *Encyclopedia of Biostatistics*, T Colton and P Armitage (eds). John Wiley & Sons, Inc.: 1997; pp. 3304-3305.
20. Dixon D: "Treatment-Covariate Interaction." In: *Encyclopedia of Biostatistics*, T Colton and P Armitage (eds). John Wiley & Sons, Inc.: 1997; pp.4559-4561.
21. Ellenberg JH, Dixon DO: "National Institutes of Health (NIH)." In: *Encyclopedia of Biostatistics, 2nd Edition*, P Armitage and T Colton (eds). John Wiley & Sons, Inc.: 2005; pp. 3603-3608.

BOOK REVIEWS:

1. Dixon DO: Review of *Bayesian Methods and Ethics in a Clinical Trial Design*, edited by Joseph B. Kadane. *Controlled Clinical Trials* **18**:87-89, 1997.
2. Dixon DO: Review of *Bayesian Approaches to Clinical Trials and Health-Care Evaluation* by DJ Spiegelhalter, KR Abrams, JP Myles. *Clinical Trials* **1**:473-474, 2004.

LETTERS TO EDITOR:

1. Dixon DO: "Assessing New Cancer Treatments: Regarding T.M. Morgan's 'Analysis of Duration of Response'." *Controlled Clinical Trials* **10**:231-233, 1989.
2. Dixon DO and Pennello G. *Controlled Clinical Trials* **22**:548-550, 2001.

ABSTRACTS:

1. Costanzi J, Al-Sarraf M, Dixon D: "Chemoimmunotherapy for disseminated melanoma (DM): A SWOG Study." *AACR and ASCO Proceedings* **20**:362, 1979.
2. Salmon S, Alexanian R, Dixon D: "Non-cross resistant combination chemotherapy improves survival in multiple myeloma." *Blood* **54**:207a, 1979.
3. Costanzi JJ, Al-Sarraf M, Dixon DO: "Chemotherapy for disseminated melanoma (DM): A SWOG study." *AACR and ASCO Proceedings* **21**:474, 1980.
4. Salmon SE, Dixon D: "Addition of Levamisole to chemotherapy improves survival in multiple myeloma." *Blood* **58**:168a, 1981.
5. Coltman CA Jr, Dixon DO: "Second malignancies complicating Hodgkin's disease: A Southwest Oncology Group ten year follow-up." *ASCO Proceedings* **1**:165, 1982.
6. Fielder KL, Jones SE, Dixon DO, Grozea PN, O' Bryan RM, Costanzi JJ, Balcerzak SP: "Prevention of central nervous system relapse in unfavorable histology non-Hodgkin's lymphoma: A Southwest Oncology Group study." *Blood* **62**:212a, 1983.
7. Dixon DO: "Comparing treatments within subgroups for censored exponential survival data." *Biometrics* **39**:803, 1983.
8. Bull FE, Baker LH, Bonnet JD, Dixon DO: "Phase II trial of Aclacinomycin A in advanced colorectal cancer using two dosage schedules: A Southwest Oncology Group study." *ASCO Proceedings* **3**:149, 1984.
9. Jones S, Grozea P, O' Bryan R, Balcerzak S, Costanzi J, Athens J, Fabian C, Dabich L, Dixon D: "Chemotherapy with Cyclophosphamide, Adriamycin, Vincristine, and Prednisone (CHOP) alone or with Levamisole or Levamisole plus BCG for non-Hodgkin's lymphoma (NHL): A Southwest Oncology Group study." *ASCO Proceedings* **3**:237, 1984.
10. Fabian C, Sayre R, Dixon D, Mansfield C: "Response rates as a function of age in Hodgkin's disease: A SWOG study." *ASCO Proceedings* **3**:240, 1984.

11. Barlogie B, Alexanian R, Dixon D: "Novel prognostic variables associated with drug resistance and survival in multiple myeloma." *Blood* **64**:178a, 1984.
12. Hall R, Dixon D, Keating M, Freireich E, Barlogie B: "Nucleic acid cytometry in adult acute lymphoblastic leukemia." *Blood* **64**:190a, 1984.
13. Grose WE, Dixon DO: "Distant metastasis in patients with head and neck squamous cell carcinoma." *ASCO Proceedings* **4**:148, 1985.
14. Neilan BA, Dixon DO, Jones SE, Lipschitz DA, Miller TP: "Age and treatment outcomes in advanced diffuse histiocytic lymphoma. The Southwest Oncology Group Experience." *ASCO Proceedings* **4**:199, 1985.
15. Grozea PN, DePersio EJ, Coltman CA Jr, Fabian CJ, Morrison FS, Dixon DO, Jones SE: "Chemotherapy alone vs. combined modality treatment for stage III Hodgkin's disease: A five-year follow-up of Southwest Oncology Group study #7518." *ASCO Proceedings* **4**:201, 1985.
16. Weick J, Hewlett J, Antunez A, Dixon D: "Radiation therapy with and without chemotherapy in limited stage (I, IE, II, IIE) nonHodgkin's lymphoma: A Southwest Oncology Group study." *ASCO Proceedings* **4**:206, 1985.
17. Lee J, Dixon D, Keating M, Gutterman JU, Talpaz M: "Chronic lymphocytic leukemia: A multivariate regression analysis of 325 cases." *Blood* **66**:178a, 1985.
18. Alexanian R, Barlogie B, Dixon D: "High dose dexamethasone for resistant multiple myeloma." *Blood* **66**:212a, 1985.
19. Durie BGM, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, Dabich L, Salmon S, Files JC, Costanzi JJ: "Improved survival duration with combination chemotherapy induction for multiple myeloma." *Blood* **66**:214a, 1985.
20. Alexanian R, Barlogie B, Dixon D: "Update of VAD for resistant multiple myeloma." *ASCO Proceedings* **5**:167, 1986.
21. Coltman CA Jr, Dahlberg S, Jones SE, Miller TP, Dana BW, McKelvey EM, Hartsock RJ, Dixon DO: "CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: A twelve year Southwest Oncology Group follow up." *ASCO Proceedings* **5**:197, 1986.
22. Kantarjian H, Keating M, Dixon D, Walters R, Talpaz M, McCredie K, Freireich E: "A multivariate analysis of characteristics of accelerated disease in chronic myelogenous leukemia." *ASCO Proceedings* **5**:269, 1986.
23. Andersson BS, Dixon DO, Estey E, Freireich E, Keating M, McCredie KB, Walters R, Beran M: "Plasma thymidine kinase predicts remission in acute myeloid leukemia." *AACR Proceedings* **27**:163, 1986.

24. Lee J, Dixon D, Keating M, Gutterman J, Talpaz, M.: "Prognosis of chronic lymphocytic leukemia: A multivariate regression analysis of 325 cases." *AACR Proceedings* **27**:196, 1986.
25. Kantarjian H, Dixon D, Lee J, Keating M, Talpaz M: "Improved prognostic prediction in patients with chronic lymphocytic leukemia (CLL) by the combined use of a regression model and Rai staging." *Blood* **68**:201a, 1986.
26. Walters R, Kantarjian H, Dixon D, Keating M, Estey E, Beran M, Andersson B, McCredie K, Freireich E, Barlogie B: "M.D. Anderson experience with acute lymphocytic leukemia." *ASCO Proceedings* **6**:152, 1987.
27. Skinner W, Childs C, Andersson B, Dixon D, McCredie K, Beran M: "Leukemic cell growth in response to colony stimulating factor (GM-CSF); an indicator of maturation in human acute myeloid leukemia." *AACR Proceedings* **28**, 1987.
28. Spinolo JA, Dicke KA, McCredie KB, Dixon DO, Horwitz LJ, Jagannath S, Spitzer G: "Remission intensification with high-dose cyclophosphamide, BCNU and VP-16 (CBV) and autologous bone marrow transplantation (ABMT) in acute myelogenous leukemia (AML)." *Blood* **70**:300a, 1987.
29. Lippman SM, Peters EJ, Wargovich MJ, Dixon DO, Dekmezian RH, Morice RC, Hong WK: "Bronchial micronuclei (MN) as a marker of an "early" intermediate endpoint of carcinogenesis in the tracheobronchial epithelium." *AACR Proceedings* **30**:231, 1989.
30. Dixon DO: "Bayesian subset analysis." *Biometric Bulletin* **7**:10, 1990.
31. Dixon DO, Shapiro SH: "Some considerations in the early stopping of clinical trials for efficacy." *Clinical Trials* **3**:198, 2006.

SUPERVISORY TEACHING:

Advisory Committees:

Member, Thesis Advisory Committee, Shelly Carter-Campbell, 9/88-7/89, University of Texas School of Public Health

Student directly supervised:

George W. Divine, Ph.D., 12/87, University of Texas School of Public Health.

INVITATIONS TO NATIONAL OR INTERNATIONAL CONFERENCES:

Invited Speaker, Comparing Treatments within Subgroups for Censored Exponential Survival Data, Biometric Society (ENAR), Nashville, TN, 3/83.

Invited Speaker, Prognostic Factors in Clinical Stages III-IV Hodgkin's Disease, International Workshop on Treatment Strategy in Hodgkin Disease, Paris, France, 6/89.

Invited Speaker, Bayesian Subset Analysis, Biometric Society (ENAR), Baltimore, MD, 4/90.

Invited Speaker, AIDS Vaccine Trials: Some Design Issues Including Sample Size Calculation (with Wasima Rida), Annual Joint Statistics Meetings, Atlanta, GA, 8/91.

Invited Speaker, Subgroup Analyses in Clinical Trials: A Bayesian Approach, Annual American Public Health Association Meeting, Atlanta, GA, 11/91.

Invited Speaker, Subset Analysis in Clinical Trials: A Bayesian Perspective, Drug Information Association Annual Meeting, Washington, D.C., 6/94.

Invited Speaker, Monitoring Safety and Efficacy in International Clinical Trials: NIH Perspective, Annual Update on HIV Vaccine Research in Thailand, Bangkok, Thailand, 3/99.

Invited Speaker, Some History of Data and Safety Monitoring Boards (DSMB). International Association for Dental Research/American Association for Dental Research Annual Meeting, Baltimore, MD, 3/05.

Invited Speaker, Role of the Society for Clinical Trials in Influencing Public Policy. Society for Clinical Trials Annual Meeting, Portland, OR, 5/05.

Invited Speaker, Stopping Clinical Trials Overseen by Data and Safety Monitoring Boards. Annual PRIM&R Advancing Ethical Research Conference, Orlando, Florida, 11/08.

INVITED PRESENTATIONS:

February, 1975

"Minimum Bayes Risk t Intervals for Comparisons Suggested by the Data." Annual Meeting, Florida Chapter, American Statistical Association, Gainesville, Florida, with D. B. Duncan.

January, 1979

"Overview of the Work in a Statistical Office for a Cancer Clinical Trials Cooperative Group." University of Texas School of Public Health, Houston, Texas.

February, 1979

"Minimum Bayes Risk Interval Estimates." University of Texas School of Public Health, Houston, Texas and Texas A&M University, College Station, Texas.

March, 1979

"Are We Overanalysing Our Data?" Southwest Oncology Group Meeting, Albuquerque, New Mexico.

June, 1979

"Multiple Testing in the Two-Way Table." Southern Regional Education Board Summer Research Conference in Statistics, Arkadelphia, Arkansas.

June 7, 1983

"Comparing Treatments in Subgroups for Censored Exponential Survival Data." Department of Biostatistics, The Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland.

September 23, 1983

"Comparing Treatments in Subgroups for Censored Exponential Survival Data." Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.

June 8, 1984

"Sample Size in Cancer Clinical Trials." Section of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

September 21, 1984

"Prognostic Factors in Multiple Myeloma." Grand Rounds, M.D. Anderson Hospital and Tumor Institute, Houston, Texas.

November 4, 1985

"Analysis of Survival Times in Chronic Lymphocytic Leukemia." John L. McClellan Memorial Veterans Hospital, Little Rock, Arkansas.

March 12, 1987

"Multiple Comparisons in Relative Risk Regression: Extension of the k -Ratio Method." Fifth Annual Conference on Biomedical Engineering Research in Houston and Fifth Annual Clinical Engineering Symposium, Houston, Texas.

March 14, 1989

"Bayesian Analysis in Medical Research - - Two Examples." Houston Area Chapter, American Statistical Association, Houston, Texas.

June 27, 1991

"Urgency in AIDS Clinical Research: Origins and Implications." Introduction to Clinical Trials Course, The Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland.

April 14, 1993

"Quality of Clinical Trial Databases." Department of Biostatistics, The Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland.

May 29, 1998

"Some Considerations in Determining the Impact of Combination Antiretroviral Therapy on Clinical Progression Rates." Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts.

June 2, 2006

"Role of DSMBs in Detecting and Confirming Safety Problems." Annual Harvard/Schering-Plough Workshop, Harvard School of Public Health, Boston, Massachusetts.

DATE OF LAST REVISION: December 2008